Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Sulfur-smelling (rotten egg) burps are a commonly reported side effect of Wegovy (semaglutide), largely because the medication slows stomach emptying and allows food to linger and release hydrogen sulfide gas. For most people this is unpleasant but harmless, and it often eases with smaller meals, fewer high-sulfur foods, and time as the body adjusts to the dose. Less often, foul-smelling burps paired with severe abdominal pain, ongoing vomiting, fever, or yellowing skin can point to pancreatitis, gallbladder problems, gastroparesis, or an H. pylori infection that needs prompt care. There are several factors that determine which situation applies to you, so review the complete details below before deciding whether to wait it out or call your prescriber.
If you are unsure where your symptoms fall on that spectrum, a free, instant online symptom check can help you sort routine GLP-1 side effects from warning signs in just a few minutes, giving you clearer language to bring to your clinician and a smarter sense of your next step.
Last reviewed for medical accuracy: 09/13/2026
If you’re taking Wegovy (semaglutide) for weight management, you may notice a range of digestive symptoms. Burping sulfur-smelling gas can be one of them. Below, we’ll explain why this happens, how common it is among wegovy side effects, and what you can do to find relief—without causing unnecessary worry.
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for chronic weight management. By mimicking a natural gut hormone, it helps you feel fuller and reduces appetite. However, altering gut motility and digestive secretions can lead to side effects, particularly in the gastrointestinal (GI) tract.
Common GI wegovy side effects include:
Although less frequently mentioned in the official prescribing information, changes in gas odor and frequency—such as sulfur-smelling belches—can occur as digestion slows and gut flora adjust.
Normal digestion produces gases like nitrogen, oxygen, hydrogen, carbon dioxide and sometimes methane. Sulfur-containing compounds (primarily hydrogen sulfide) are responsible for the characteristic “rotten egg” smell. Factors that increase sulfur-containing gas include:
Because Wegovy slows gastric emptying and changes intestinal transit times, you might notice more pronounced gas odors as your gut adapts.
While clinical trials for Wegovy list nausea, vomiting, diarrhea and constipation as the most common GI side effects, less common symptoms such as changes in gas odor are not systematically tracked but do occur. Anecdotally, some patients report:
These symptoms often appear early in treatment or after dose increases and tend to diminish over weeks to months as your body adjusts.
Most cases of sulfur burps on Wegovy are benign and can be managed with lifestyle and dietary tweaks:
Most sulfur burps on Wegovy are mild and transient. However, seek medical attention if you experience any of the following:
These symptoms could indicate a more serious condition requiring prompt evaluation.
If you’re unsure whether your symptoms are typical or if they warrant a doctor’s visit, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you understand when to seek care and which questions to ask your healthcare provider.
Wegovy’s ability to reduce appetite and promote weight loss can bring significant health benefits, especially for individuals with obesity or related conditions (e.g., type 2 diabetes). When managed well, most digestive side effects—including sulfur-smelling burps—are temporary and improve over time. Keep in mind:
Always discuss any new or worsening symptoms with your healthcare provider. If burping sulfur-smelling gas is accompanied by severe pain, dehydration, or any alarming signs, speak to a doctor right away. Proper guidance ensures your safety and the best possible outcome from your wegovy side effects management plan.
By understanding why sulfur burps happen and using practical strategies to manage them, you can stay on track with your weight-management goals on Wegovy. Remember: most gas-related side effects are temporary. If concerns persist, reach out to your healthcare provider or use the Ubie Symptom Checker to decide on next steps.
(References)
* Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10:996179. doi: 10.3389/fpubh.2022.996179. Epub 2022 Oct 20. PMID: 36339230; PMCID: PMC9631444.
* Xiong S, Gou R, Liang X, Wu H, Qin S, Li B, Luo C, Chen J. Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023. Diabetes Ther. 2024 Aug;15(8):1717-1733. doi: 10.1007/s13300-024-01594-7. Epub 2024 May 22. PMID: 38776037; PMCID: PMC11263519.
* Bacus C, South TL, Raudszus S, Johansen OE. Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product. Obes Pillars. 2024 Dec;12:100138. doi: 10.1016/j.obpill.2024.100138. Epub 2024 Sep 30. PMID: 39416284; PMCID: PMC11480229.
* Himmerich H. [Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]. Nervenarzt. 2025 May;96(3):247-254. doi: 10.1007/s00115-025-01813-x. Epub 2025 Mar 5. PMID: 40042613; PMCID: PMC12058874.
* Alali S, Al-Otaibi W, Ashodian K, Achour N, Almulla A, Mutlaq H. A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait. Front Nutr. 2025;12:1590379. doi: 10.3389/fnut.2025.1590379. Epub 2025 May 19. PMID: 40458827; PMCID: PMC12127183.
* Kofman K, Ouanounou A. Oral Health Considerations and Dental Management Guidelines for Semaglutide Medications. Can J Diabetes. 2026 Apr 10. doi: 10.1016/j.jcjd.2026.03.008. Epub 2026 Apr 10. PMID: 41967795.
* Guo X, Zhang J, Li Q, Ye Z, Yuan S. Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database. Diabetes Obes Metab. 2026 Oct;28(10):8936-8945. doi: 10.1111/dom.71025. Epub 2026 Jul 13. PMID: 42443144; PMCID: PMC13538822.
* Bijoch J. Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies. J Clin Med. 2026 Jul 9;15(14). doi: 10.3390/jcm15145358. Epub 2026 Jul 9. PMID: 42513271; PMCID: PMC13410358.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.